
An oral treatment containing 16 cultivated bacterial strains was associated with fewer bloodstream infections following donor stem cell transplantation, according to a phase 1b trial published November 3, 2026, in Nature Medicine. In a randomized efficacy population of 34 transplant recipients, 2 of 20 receiving the SER-155 regimen developed bloodstream infections, compared with 6 of 14 given placebo; the study was designed primarily to test safety and bacterial engraftment rather than definitively establish infection prevention.
A disrupted gut microbiome can increase infection risk after transplantation
Allogeneic hematopoietic cell transplantation (allo-HCT) uses blood-forming cells from a donor to treat certain blood cancers and other diseases. Chemotherapy conditioning, antibiotics, immune suppression and damage to intestinal tissues can destabilize the gastrointestinal (GI) microbiome. These changes may make it easier for harmful organisms to expand and enter the circulation, potentially causing a bloodstream infection.
The gut is more than a location for food digestion. Our earlier explainer on how gut microbes communicate with other organs described links between microbial communities, metabolic functions and immune responses. The transplant setting makes intestinal barrier integrity and immune function particularly important.
SER-155 is a defined, oral live biotherapeutic containing 16 bacterial strains grown individually and combined into capsules. It is not a conventional probiotic supplement or a fecal transplant. Investigators designed the mixture to establish itself in the gut and potentially influence microbial composition, intestinal barrier function and inflammatory signaling.
The randomized analysis found eight bloodstream infections in 34 recipients
The study included an initial open-label cohort of 15 recipients and a second, partially randomized, placebo-controlled cohort of 45. Only 34 participants in the second cohort received their assigned intervention and proceeded to transplantation: 20 in the active-regimen group and 14 receiving placebo. The headline infection analysis concerns these 34 patients rather than everyone enrolled.
Through day 100 after transplantation, infections occurred in 2 of 20 treated participants (10.0%) versus 6 of 14 placebo recipients (42.9%). The observed absolute difference was approximately 33 percentage points, equivalent to a 77% relative reduction in infection incidence. The paper reported P = 0.0423 for this secondary efficacy endpoint, but only eight events occurred. This makes the estimate vulnerable to chance variation, and the authors reported wide uncertainty intervals.
Every bloodstream infection arose between days 4 and 15, before neutrophil recovery. Two infections were associated with fatal outcomes, both among placebo recipients. Those figures do not demonstrate improved survival; the study was much too small to establish a mortality effect.
Rates of other secondary outcomes, including GI infection, febrile neutropenia and grade 2 or higher acute graft-versus-host disease (GvHD), did not differ significantly between groups. GvHD occurs when donor immune cells attack the transplant recipient’s tissues. That biological complexity is another reminder that T cell behavior in cancer and chronic infection cannot be reduced to a single laboratory marker or one immune pathway.
As an exploratory measure, participants given SER-155 received systemic antibacterial or antifungal treatment for adverse events for an average of 9.2 days versus 21.1 days in the placebo group. It is a potentially useful secondary observation, not established evidence of reduced antimicrobial use in routine transplant care.
The trial tested antibiotics followed by bacterial treatment, not SER-155 alone
The intervention consisted of four days of oral vancomycin to condition the existing gut microbiome, followed by ten days of SER-155. Treatment courses occurred before and after transplantation. Vancomycin was intended to create an ecological opening so the introduced strains could establish themselves. Placebo patients did not receive vancomycin conditioning, in part because exposing them to the antibiotic without subsequent bacterial replacement could have disrupted their microbiome unnecessarily.
The clinical result therefore reflects the combined effects of vancomycin conditioning and SER-155. The trial cannot determine whether the observed infection difference came from the administered bacteria, the antibiotic pretreatment or their interaction. This limitation is explicitly acknowledged by the investigators and should accompany any claim about efficacy.
All 16 administered strains engrafted, but the mechanism remains uncertain
Safety and bacterial engraftment were the trial’s primary endpoints. Researchers detected all 16 SER-155 strains in treated recipients and reported a median of 11.5 strains after the first course. Gut microbial composition differed significantly between treatment groups, providing evidence that the regimen altered the intestinal ecosystem.
The researchers also explored markers of GI barrier function and circulating inflammatory molecules. Their findings were consistent with a possible protective effect on the intestinal lining and modulation of immune signaling, but did not conclusively establish how bloodstream infections were prevented. The specific origins of the infection-causing organisms could not be identified with certainty, even when the species were known to inhabit the intestine.
These results align with growing interest in microbial therapeutics as an adjunct to cancer care, a field that also needs to account for the profound systemic effects of advanced disease highlighted in our coverage of cancer-associated cachexia. However, findings in one clinical condition should not automatically be generalized to another.
Safety findings were encouraging but limited by the small trial
SER-155 was generally tolerated with a safety profile similar to placebo. Investigators reported no serious adverse events, deaths or infections attributable to the administered SER-155 strains. Diarrhea and nausea were common adverse events, generally mild or moderate when associated with treatment.
Four participants died in the open-label cohort and four in the randomized cohort, including two in each randomized treatment arm. None was considered related to SER-155. Those deaths reflect the vulnerability of the underlying transplant population and reinforce the need for larger studies with sufficient follow-up to evaluate safety and meaningful clinical outcomes.
The paper also notes imbalances in some transplant-related treatments, including greater use of post-transplant cyclophosphamide in the placebo arm. An exploratory adjusted analysis supported the direction of the infection finding, but such analyses cannot eliminate residual uncertainty in a trial of this size.
A larger study is needed before the regimen can change clinical care
The central question is whether a reproducible set of cultivated bacteria can reliably lower infection risk in people undergoing highly intensive treatment. This first-in-human, phase 1b study offers an encouraging preliminary signal. Its small efficacy sample, secondary infection endpoint, inability to disentangle vancomycin from SER-155 and lack of significant differences in other clinical outcomes prevent a definitive conclusion.
Seres Therapeutics developed SER-155 and publicly announced the peer-reviewed findings, making commercial involvement relevant to interpreting the research. Independent replication and larger controlled trials are needed to clarify the durability of engraftment, infection outcomes, antibiotic requirements and potential effects on graft-versus-host disease or survival.
SER-155 remains investigational. The study does not support use of ordinary probiotic supplements to prevent infections in immunocompromised patients, nor does it justify trying to recreate the bacterial treatment regimen outside clinical supervision. The next trials will need to establish whether the early infection reduction is reproducible and whether its potential benefits outweigh the complexities of delivering a live bacterial therapy during stem cell transplantation.
References
- Ponce DM, et al. A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial. Nature Medicine. Published November 3, 2026. DOI: 10.1038/s41591-026-04686-y.
- Seres Therapeutics. Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients. November 3, 2026. Company announcement.